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Lymphocyte signaling: Cbl sets the threshold for autoimmunity
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Cbl, a negative regulator of immune signaling, has
recently been shown to act as a ubiquitin–protein ligase.
Further, two new papers describing Cbl-b-deficient
mice suggest that Cbl-b sets the threshold of signaling
in T and B cells and prevents the development
of autoimmunity. 
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Members of the Cbl family of intracellular proteins, c-Cbl
and Cbl-b are prominent substrates for tyrosine phospho-
rylation in immune cells [1,2]. At least four Cbl family
members have been described: c-Cbl, the related protein
Cbl-b, Caenorhabditis elegans Cbl (Sli-1) and Drosophila Cbl
(D-Cbl) (Figure 1). Cbl is the mammalian ortholog of Sli-1
of C. elegans, and was originally noted for its negative regu-
lation of signaling downstream of v-ErbB, the oncogenic
form of the epidermal growth factor receptor. In the
immune system, c-Cbl profoundly inhibits the function of
T, B and mast cells by downregulating kinases such as
Zap-70 and Syk [3–6]. While past studies have linked
c-Cbl to protein turnover, the precise molecular basis for
Cbl function has only recently become evident with the
discovery that Cbl can recruit components of the ubiquitin-
conjugation pathway [6–8] and act as an ubiquitin–protein
ligase [9]. Furthermore, two new papers describing Cbl-b-
deficient mice reveal a provocative connection between
Cbl-b-mediated protein degradation and the regulation of
the threshold of T- and B-cell signaling leading to the
development of autoimmunity [10,11].
Cbl as a ubiquitin ligase
Ubiquitination is a process by which cells can discriminate
and target specific proteins for degradation from a vast
array of intracellular constituents and surface proteins. It is
regulated by a series of enzymes (termed E1, E2, E3 and
E4) that, in several cyclic steps, transfer the 8,565 Da ubiq-
uitin polypeptide to a host protein, tagging it for degrada-
tion by the 26S proteasome (Figure 2a). The process is
initiated by the E1 ubiquitin-activating enzymes that
mediate the ATP-dependent charging of ubiquitin with
the formation of a thioester bond between a cysteine
residue in the E1 enzyme and the carboxyl terminus of
ubiquitin. This high-energy bond is then transferred to the
E2 ubiquitin-conjugating enzymes, which, either by them-
selves or in conjunction with E3 ubiquitin–protein ligases,
transfer ubiquitin monomers or polymers to target sub-
strates. Polyubiquitin chain synthesis can be increased by
other factors, such as E4 proteins, and decreased by de-
ubiquitinating proteases. Eventually, ubiquitin-tagged
polypeptides are degraded into peptides by the 26S protea-
some. Although the exact mechanism responsible for selec-
tivity of substrates is not known, each of the E1, E2 and E3
enzymes are encoded by genes comprising a supergene
family, thereby providing specificity amongst the different
isoforms. The full range of enzymes and their specificities
are only just beginning to be elucidated. 
Each of the Cbl proteins has a conserved phosphotyrosine-
binding domain (PTB) and a small zinc-binding domain
termed the RING finger domain, while c-Cbl and Cbl-b
have an additional proline-rich region and multiple tyro-
sine phosphorylation sites (Figure 1). The different regions
in Cbl cooperate to facilitate target selection and ubiquiti-
nation. While the PTB domain binds to specific phospho-
tyrosine motifs in target proteins, the RING finger recruits
an E2 enzyme, which in this case is the human ubiquitin-
conjugating enzyme 7 (UbcH7) [8]. The RING finger
itself acts as an E3 ligase and promotes conjugation of
ubiquitin to the target substrate [9]. Cbl proteins therefore
Figure 1
Schematic representation of the Cbl family members, showing the four
presently known Cbl proteins, c-Cbl, Cbl-b, C. elegans Cbl (Sli-1) and
Drosophila Cbl (D-Cbl). Each has a conserved phosphotyrosine-binding
domain (PTB) and a RING finger domain, while c-Cbl and Cbl-b have
an additional proline-rich region and multiple tyrosine phosphorylation
sites (marked with Y). The PTB and RING finger regions are conserved,
while the carboxy-terminal regions diverge between family members.
The forms of c-Cbl that contain either a deletion (70Z-cbl) or a point
mutation at Cys381 (C381A) are also shown.
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combine the specificity of PTB substrate selection with
the RING finger E2-binding and ligase activity within a
single protein (Figure 2b). Mutant forms of Cbl that
contain deletions (such as 70Z/cbl) or a point mutation
(such as the cysteine to alanine mutation at position 381)
are defective in promoting ubiquitination [1] (Figure 1).
Ubiquitination sets the threshold of immune cell signaling
With their capacity to selectively degrade key intracellu-
lar proteins, c-Cbl and Cbl-b are ideally suited to nega-
tively regulate aspects of immune cell function. Indeed,
c-Cbl-deficient mice show hypercellularity of lymphoid
organs and altered positive selection in the thymus, and
cells from these mice show increased intracellular protein
phosphorylation and surface receptor expression [1]. Two
recent reports have provided exciting evidence for a
more subtle role for Cbl-b in regulating the threshold of
signaling in T and B cells [10,11]. T cells from Cbl-b-
deficient mice show enhanced proliferation and inter-
leukin-2 (IL-2) production in response to triggering of
the T-cell receptor, while B cells show potentiation of
proliferation in response to B-cell receptor and
CD40 triggering [10]. 
In an extension of this phenotype, the lowering of the
threshold caused by the loss of Cbl-b correlated with an
increased susceptibility to the development of autoimmu-
nity. These mice had an increased presence of autoanti-
bodies reactive to double-stranded DNA and showed
signs of spontaneous autoimmunity [10], or an increased
susceptibility to experimental autoimmune encephalo-
myelitis (a mouse model for multiple sclerosis) [11]. The
difference in the onset of autoimmunity observed in
these two studies could be related to the different genetic
background or ages of the host mice, or to the presence of
infectious reagents or to different environments. The
important point is that both studies support the exciting
notion that Cbl-b is a key regulator of the susceptibility to
autoimmunity, findings with potential relevance to
human autoimmune disorders, such as multiple sclerosis
or type 1 diabetes. 
Which intracellular protein targeted by Cbl-b could
account for this phenotype? Many phosphoproteins associ-
ate with Cbl-b including phospholipase Cg (PLCg ), phos-
phoinositol (PI) 3-kinase, the kinases Lck, Fyn, Zap-70
and Syk, and the adaptor proteins Slp-76 and Vav. Despite
the many targets, Cbl-b-deficient cells showed a selective
enhancement of Vav phosphorylation, indicating that Cbl-
b is a negative regulator of the phosphorylation of this
protein — an important finding, given that Vav is a key
guanine nucleotide exchange factor for the Rho family of
GTP-binding proteins (Rac1, Rac2 and Cdc42) in lym-
phoid cells. Vav guanine nucleotide exchange activity is
upregulated by Lck-mediated phosphorylation (and possi-
bly also by other kinases). 
Further, the GTP-bound form of the Rac1 GTPase pro-
motes actin polymerization, the organization of the
cytoskeleton and receptor aggregation [12]. In accordance
with this phenotype, the conversion of Rac1 to a GTP-
bound active form is enhanced in Cbl-b-deficient cells [11].
Paradoxically, despite its binding to Cbl-b, Vav itself is
unlikely to be directly regulated by Cbl-b because its
expression is unchanged in these cells. Instead, an
upstream regulator of the Vav–Rac1 pathway is more
likely to be responsible for the phenotype (Figure 3). The
identity of the upstream regulator is unclear, but it is pre-
sumably a regulatory factor (i.e. for localisation or inhibi-
tion of phosphatases) or a kinase other than Lck. In either
case, a connection with the Vav–Rac 1 pathway is compati-
ble with the central role of this pathway in actin-depen-
dent T-cell receptor cap formation [13,14]. In addition, T
cells from Vav-deficient mice have been found to be
impaired in T-cell receptor signaling [15,16]. 
Figure 2
Mechanisms of ubiquitination. (a) Ubiquitination targets specific
proteins for degradation. The process is regulated by a series
of enzymes (termed E1, E2, E3 and E4) that, in cyclic steps,
transfer the ubiquitin polypeptide to a host protein as a marker
for degradation by the 26S proteasome. E1SH (single
ubiquitin-activating enzyme) catalyzes formation of a complex
composed of a covalent E1S–ubiquitin (E1S–Ub) and non-covalently
bound ubiquitin adenylate (AMP–Ub). E2SH (ubiquitin-conjugating
enzyme) catalyzes a transthiolation reaction leading to
E2S–ubiquitin thiolester (E2S–Ub). E3 (ubiquitin–protein isopeptide
ligase) binds the target protein and catalyzes isopeptide bond
formation. (b) Cbl-mediated ubiquitination. The PTB domain binds
to specific tyrosine-phosphorylated proteins, while the RING finger
recruits the human E2 ubiquitin-conjugating enzyme 7 (UbcH7).
As an E3 ligase, the RING finger can then facilitate ubiquitin
conjugation to the target substrate.
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Is Cbl-b linked to CD28 or T-cell receptor signaling
pathways? 
Given that Cbl-b alters the threshold requirements for sig-
naling, the next key question was whether Cbl-b is linked
to co-stimulation through the T-cell co-receptor CD28.
Optimal T-cell activation requires two signals, one sent by
the T-cell receptor and a second co-stimulatory signal from
CD28 when bound to its ligands CD80 or CD86 [17].
Indeed, CD28 (and the related CTLA-4 molecule) is
widely accepted as setting the threshold of signaling
through the T-cell receptor complex. CD28 interacts with
PI 3-kinase and the adaptors Grb2 and Vav, and can induce
Vav phosphorylation (for reviews, see [18,19]). Mutations
in the CD28 cytoplasmic tail can also cause a  concomitant
loss of Vav phosphorylation and co-stimulation [20]. 
The most compelling evidence in support of a connection
between Cbl-b and CD28-mediated co-stimulation is the
observation in the recent studies that the loss of Cbl-b in
CD28-deficient mice restores high levels of proliferation
that are absent in T cells from Cbl-b+/+ CD28-deficient
mice [10,11]. This finding could be interpreted to indicate
that the Cbl-b mutation uncouples proliferation from
CD28, or that the loss of Cbl-b simply upregulates prolif-
eration mediated by the T-cell receptor. The Cbl-b-
induced increase in proliferation is approximately
equivalent to that achieved with co-stimulation. If Cbl-b is
directly linked to CD28, co-stimulation should be defec-
tive in Cbl-b-deficient T cells. Instead, CD28 enhances
proliferation to a similar extent in T cells from both Cbl-b
heterozygous and homozygous deficient mice [10,11].
Further, Chiang et al. [11] found that CD28 can still
enhance Vav phosphorylation and Rac1 activation in these
cells. Although this augmentation is less evident in Bach-
maier et al.’s study [10], these findings cast some uncer-
tainty as to whether Cbl is directly connected to CD28. If
the connection is indeed real, CD28 co-stimulation can
only be partially dependent on the protein. These obser-
vations, combined with the finding that CD28 co-stimula-
tion is normal in Vav-deficient T cells [13], are more
supportive of a connection with T-cell receptor signaling,
which may then provide Cbl-dependent signals that coop-
erate with CD28 to generate optimal signaling in T cells. 
Further work will obviously be needed to clarify the con-
nection between Cbl-b and T-cell receptor and CD28 sig-
naling. These new studies, however, point to an exciting
new advance in our understanding of how the selective
destruction of intracellular proteins by Cbl-b can regulate
the threshold of lymphocyte receptor signaling and the
onset of autoimmunity.
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